AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Search Results for: "National Institute of Allergy and Infectious Diseases"

NIAID to Fund Further Study of Dapivirine Vaginal Ring for HIV Prevention Investment in HOPE Trial Augments Development of Next-Generation Prevention Tools

NIAID image - vaginal ring - ASPIRE study

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today that it would move forward with an open-label extension study of an HIV prevention tool for women: a silicone ring that continuously releases the experimental antiretroviral drug dapivirine in the vagina. The new study builds on…

Research Update: NIH’s Dr. Dieffenbach on CROI 2016 (Video)

drcarl

As the 2016 Conference on Retroviruses and Opportunistic Infections (CROI)  came to a close in Boston on February 25, we spoke with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), about some of the highlights of the HIV research presented there. He notes that there…

Vaginal Ring & PrEP Updates from CROI with NIH’s Dr. Carl Dieffenbach (Video)

DrDieffenbach

New scientific findings to inform HIV prevention efforts were among the key highlights shared at CROI yesterday, according to Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). After another day full of presentations on the latest in HIV science at the 2016 Conference on…

NIH-Funded Study Finds Critical Population Adheres to PrEP with Coordinated Care

blackmsm

New findings suggest that black men who have sex with men (BMSM) with access to a novel coordinated care program can adhere to pre-exposure prophylaxis (PrEP), a medication regimen that helps prevent HIV infection in uninfected individuals. Researchers reported their results today at a press conference at the Conference on Retroviruses and Opportunistic Infections (CROI)…

NIH’s Dr. Carl Dieffenbach Shares Highlights from Start of CROI 2016 (Video)

croiday1

After the first full day of sessions at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston yesterday, February 23, we caught up with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), to get his take on some of the key highlights of…

NIH-Funded Study Finds Effect of PrEP on Bone Density is Reversible

nih logo

The slight loss in bone mineral density associated with HIV pre-exposure prophylaxis (PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers today at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. PrEP is an HIV prevention strategy in which at-risk HIV-negative…

Vaginal Ring Provides Partial Protection from HIV in Large Multinational Trial

Woman holding the dapivirine vaginal ring tested in the NIH-funded ASPIRE study.
Credit: International Partnership for Microbicides

NIH-Funded Study Finds Protective Effect Strongest in Women over Age 25 A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found. The ring reduced the risk of HIV infection by…

ICYMI – NIH’s Dr. Anthony Fauci Pens Op-Ed on Tools to End HIV/AIDS

Fauci

In case you missed it, last week Dr. Anthony Fauci shared an op-ed in The Washington Post: “No more excuses. We have the tools to end the HIV/AIDS pandemic.” Dr. Fauci, Director of the National Institute of Allergy and Infectious Diseases at NIH, observes, “[W]hy does this global pandemic continue to rage? It is not…